Biochemical and kinetic approaches to inhibition of multiple pathways.

[1]  R. Jackson,et al.  Computer models of anticancer drug interaction. , 1979, Pharmacology & therapeutics.

[2]  Y. Cheng,et al.  Human thymidylate synthetase. II. Derivatives of pteroylmono- and -polyglutamates as substrates and inhibitors. , 1978, The Journal of biological chemistry.

[3]  Y. Cheng,et al.  Human thymidylate synthetase derived from blast cells of patients with acture myelocytic leukemia. Purification and chracterization. , 1977, The Journal of biological chemistry.

[4]  T. Chou,et al.  Metabolism of 1- β -d-Arabinofuranosylcytosine in Human Leukemic Cells , 1977 .

[5]  W. Ensminger,et al.  The prevention of methotrexate toxicity by thymidine infusions in humans. , 1977, Cancer research.

[6]  Y. Cheng,et al.  Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients. , 1977, Biochimica et biophysica acta.

[7]  D. Keppler.  Uridine triphosphate deficiency, growth inhibition, and death in ascites hepatoma cells induced by a combination of pyrimidine biosynthesis inhibition with uridylate trapping. , 1977, Cancer research.

[8]  D. Santi,et al.  Requirement of reduced folate cofactors for cytotoxicity of 5-fluoro-2'-deoxyuridine. Abstr. , 1977 .

[9]  D. Martin,et al.  Thymidine (tdr) enhancement of antitumor activity of 5-fluorouracil (fu) against advanced murine (cd8f1) breast carcinoma. Abstr. , 1977 .

[10]  J. Bertino,et al.  Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. , 1977, Cancer research.

[11]  R. Jackson,et al.  Enzyme pattern directed chemotherapy. The effects of combinations of methotrexate, 5-fluorodeoxyuridine and thymidine on rat hepatoma cells in vitro. , 1976, Biochemical pharmacology.

[12]  R. Schimke,et al.  Regulation of folate reductase synthesis in sensitive and methotrexate-resistant sarcoma 180 cells. In vitro translation and characterization of folate reductase mRNA. , 1976, The Journal of biological chemistry.

[13]  Y. Cheng,et al.  Human deoxythymidine kinase II: substrate specificity and kinetic behavior of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia. , 1976, Biochemistry.

[14]  M. Horning,et al.  Elimination of antipyrine and benzo[a]pyrene metabolism in cultured human lymphocytes , 1976, Clinical pharmacology and therapeutics.

[15]  R. Jackson,et al.  Enzyme pattern-directed chemotherapy: synergistic interaction of 3-deazauridine with D-galactosamine. , 1976, Cancer treatment reports.

[16]  R. Moran,et al.  Folate metabolism in mammalian cells in culture. I Partial characterization of the folate derivatives present in L1210 mouse leukemia cells. , 1976, The Journal of biological chemistry.

[17]  J. Littlefield,et al.  Altered regulation of the rate of synthesis of dihydrofolate reductase in methotrexate-resistant hamster cells. , 1976, The Journal of biological chemistry.

[18]  G. Lepage,et al.  Enhancement of the antitumor activity of arabinofuranosyladenine of 2'-deoxycoformycin. , 1976, Cancer research.

[19]  C. Cass,et al.  Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin. , 1976, Cancer research.

[20]  G. Grindey,et al.  Potentiation by guanine nucleosides of the growth-inhibitory effects of adenosine analogs on L1210 and sarcoma 180 cells in culture. , 1976, Cancer research.

[21]  D. R. Dubbs,et al.  Mitochondrial and herpesvirus-specific deoxypyrimidine kinases , 1975, Journal of virology.

[22]  F. Maley,et al.  Effect of methotrexate on thymidylate synthetase in cultured parenchymal cells isolated from regenerating rat liver. , 1975, Cancer research.

[23]  A. Sartorelli,et al.  Inhibitors of alkaline phosphatase of Sarcoma 180/TG. , 1975, Biochemical pharmacology.

[24]  W. Plunkett,et al.  Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. , 1975, Cancer research.

[25]  C. Cass,et al.  Combination Therapy of Mouse Leukemia L1210 by 1-β-d-Arabinofuranosylcytosine and 6-[(4-Nitrobenzyl)thio]-9-β-d-ribofuranosylpurine , 1975 .

[26]  M. Tattersall,et al.  New approaches to cancer chemotherapy with methotrexate. , 1975, The New England journal of medicine.

[27]  C. Dave,et al.  A Simple Method for Long-Term Drug Infusion in Mice: Evaluation of Guanazole as a Model 1 , 1975, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[28]  E. Frei,et al.  The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects , 1975, Nature.

[29]  R. Moran,et al.  Chapter 5 – Approaches to the Rational Combination of Antimetabolites for Cancer Chemotherapy , 1975 .

[30]  R. Jackson,et al.  Enzyme kinetics and combination chemotherapy: an appraisal of current concepts. , 1975, Advances in enzyme regulation.

[31]  R. Harvey,et al.  Regulation in the folate pathway of Escherichia coli. , 1975, Advances in enzyme regulation.

[32]  M. Tattersall,et al.  Factors determining cell sensitivity to methotrexate: studies of folate and deoxyribonucleoside triphosphate pools in five mammalian cell lines. , 1974, European journal of cancer.

[33]  M. C. Wang,et al.  Cytidine 5'-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine. , 1974, Cancer research.

[34]  G. Bjursell,et al.  Nuclear and cytoplasmic pools of deoxyribonucleoside triphosphates in Chinese hamster ovary cells. , 1974, The Journal of biological chemistry.

[35]  G. Hahn,et al.  The roles of various biochemical effects produced by 5-fluorouracil in early growth inhibition of Bacillus cereus. , 1974, Biochemical pharmacology.

[36]  A. Bloch.  Metabolic conditioning and metabolic actuation: experimental approaches to cancer chemotherapy involving combinations of metabolites and antimetabolites. , 1974, Cancer chemotherapy reports.

[37]  A. Bloch,et al.  Prevention by testosterone of the intestinal toxicity caused by the antitumor agent 3-deazauridine. , 1974, Cancer research.

[38]  D. Schlessinger,et al.  Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia. , 1974, Cancer research.

[39]  Brockman Rw.  Biochemical aspects of drug combinations. , 1974 .

[40]  D. Santi,et al.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. , 1974, Biochemistry.

[41]  R T Schimke,et al.  Control of enzyme levels in mammalian tissues. , 2006, Advances in enzymology and related areas of molecular biology.

[42]  R. Jackson,et al.  Studies with a mathematical model of folate metabolism. , 1973, Archives of biochemistry and biophysics.

[43]  G. Grindey,et al.  Antitumor activity of N6-phenyladenosine, and inhibitor of adenosine utilization, in combination with related purine analogs. , 1973, Cancer research.

[44]  A. Orengo,et al.  Guanosine anabolism for biosynthesis of nucleic acids in Novikoff ascites rat tumor cells in culture. , 1973, Cancer research.

[45]  V. Oliverio,et al.  The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. , 1973, Cancer research.

[46]  R. Moran,et al.  Mathematical simulation of the interaction of drugs that inhibit deoxyribonucleic acid biosynthesis. , 1973, Molecular pharmacology.

[47]  D. Schlessinger,et al.  Polyene Potentiation of Antitumor Agents , 1973 .

[48]  J. Seegmiller,et al.  Properties of 5-phosphoribosyl-1-pyrophosphate amidotransferase from human lymphoblasts. , 1973, The Journal of biological chemistry.

[49]  E. Scholar,et al.  Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells. , 1973, Cancer research.

[50]  H. Wallerstein,et al.  The return of antimetabolite sensitivity in methotrexate- and 6-mercaptopurine-resistant L1210 murine leukemia by the process of adaptive selection. , 1972, Cancer research.

[51]  J. A. Nelson,et al.  Biochemical mechanisms for the synergism between 6-thioguanine and 6-(methylmercapto)purine ribonucleoside in sarcoma 180 cells. , 1972, Cancer research.

[52]  A. Paterson,et al.  Interference with nucleoside transport in mouse lymphoma cells proliferating in culture. , 1972, Cancer research.

[53]  W. Hryniuk.  Purineless death as a link between growth rate and cytotoxicity by methotrexate. , 1972, Cancer research.

[54]  J. L. Biedler,et al.  Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. , 1972, Cancer research.

[55]  G. Grindey,et al.  Interaction of drugs inhibiting different steps in the synthesis of DNA. , 1972, Cancer research.

[56]  N. Sládek.  Therapeutic efficacy of cyclophosphamide as a function of its metabolism. , 1972, Cancer research.

[57]  G. Cooper,et al.  Role of catabolism in pyrimidine utilization for nucleic acid synthesis in vivo. , 1972, Cancer research.

[58]  P. Brown,et al.  Synergistic effect of 6-mercaptopurine and 6-methylmercaptopurine ribonucleoside on the levels of adenine nucleotides of Sarcoma 180 cells. , 1972, Cancer research.

[59]  M. Hakala,et al.  Common mechanism for the passage of purine and pyrimidine nucleosides through the plasma membrane of sarcoma 180 cells (s-180). Abstr. , 1972 .

[60]  R. Moran,et al.  Combinations of drugs which interact as inhibitors of DNA biosynthesis. , 1972, Advances in enzyme regulation.

[61]  E. Roth,et al.  Acridine Orange Potentiation of Actinomycin D Uptake and Activity , 1971, Science.

[62]  M. Hakala,et al.  Adenosine kinase of sarcoma 180 cells N 6 -substituted adenosines as substrates and inhibitors. , 1971, Molecular pharmacology.

[63]  S. Ohno,et al.  Effect of the androgen-insensitivity mutation on a cytoplasmic receptor for dihydrotestosterone. , 1971, Nature: New biology.

[64]  Y. Cheng,et al.  Erythrocytic nucleoside diphosphokinase. IV. Evidence for electrophoretic heterogeneity. , 1971, Biochemistry.

[65]  R. Parks,et al.  Erythrocytic nucleoside diphosphokinase. V. Some properties and behavior of the pI 7.3 isozyme. , 1971, The Journal of biological chemistry.

[66]  D. Roberts,et al.  Methotrexate and cytosine arabinoside modulation of thymidylate synthetase activity in CCRF-CEM cells. , 1971, Cancer research.

[67]  A W Murray,et al.  The biological significance of purine salvage. , 1971, Annual Review of Biochemistry.

[68]  A. Paterson,et al.  Mechanism of the growth inhibition potentiation arising from combination of 6-mercaptopurine with 6-(methylmercapto)purine ribonucleoside. , 1970, Cancer research.

[69]  G. Neil,et al.  Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice. , 1970, Cancer research.

[70]  J. Bertino,et al.  Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue". , 1970, Cancer research.

[71]  A. Paterson,et al.  Combination chemotherapy: treatment of the Ehrlich ascites carcinoma and several drug-resistant sublines with combinations of 6-mercaptopurine and 6-(methylmercapto)purine ribonucleoside. , 1970, Canadian journal of biochemistry.

[72]  G. Lepage.  Alterations in enzyme activity in tumors and the implications for chemotherapy. , 1970, Advances in enzyme regulation.

[73]  A. Sartorelli.  Some approaches to the therapeutic exploitation of metabolic sites of vulnerability of neoplastic cells. , 1969, Cancer research.

[74]  P. Reichard,et al.  Role of effector binding in allosteric control of ribonucleoside diphosphate reductase. , 1969, Journal of molecular biology.

[75]  G. Hitchings.  Chemotherapy and comparative biochemistry: G. H. A. Clowes memorial lecture. , 1969, Cancer research.

[76]  I. Shiio,et al.  Regulation of purine ribonucleotide synthesis by end product inhibition. II. Effect of purine nucleotides on phosphoribosylpyrophosphate amidotransferase of Bacillus subtilis. , 1969, Journal of biochemistry.

[77]  G. Whitmore,et al.  Studies relating to the mode of action of methotrexate. II. Studies on sites of action in L-cells in vitro. , 1969, Molecular pharmacology.

[78]  A. Sartorelli,et al.  Studies on the mechanism of the azaserine-induced decrease in the activity of thymidine kinase. , 1969, Biochemical pharmacology.

[79]  R. Lilley,et al.  Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. , 1969, Biochemical pharmacology.

[80]  A. Gotto,et al.  Stimulatory effects of inosine and deoxyinosine on the incorporation of uracil-2-14-C, 5-fluorouracil-2-14-C, and 5-bromouracil-2-14-C into nucleic acids by Ehrlich ascites tumor cells in vitro. , 1969, Cancer research.

[81]  A. Paterson,et al.  Combination chemotherapy: synergistic inhibition of lymphoma L5178Y cells in culture and in vivo with 6-mercaptopurine and 6-(methylmercapto)purine ribonucleoside. , 1969, Cancer research.

[82]  G. Maley,et al.  The effect of methotrexate on enzymes induced following partial hepatectomy. , 1969, Cancer research.

[83]  D. Hill,et al.  Purification and properties of 5-phosphoribosyl pyrophosphate amidotransferase from adenocarcinoma 755 cells. , 1969, Biochemistry.

[84]  D. Kessel.  Some observations on the phosphorylation of cytosine arabinoside. , 1968, Molecular pharmacology.

[85]  H. Dewey,et al.  The developmental formation of liver glucose 6-phosphatase and reduced nicotinamide adenine dinucleotide phosphate dehydrogenase in fetal rats treated with thyroxine. , 1968, The Journal of biological chemistry.

[86]  S. Bushby,et al.  Trimethoprim, a sulphonamide potentiator. , 1968, British journal of pharmacology and chemotherapy.

[87]  E. Jensen,et al.  A two-step mechanism for the interaction of estradiol with rat uterus. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[88]  G. Grindey,et al.  Effects of uracil derivatives on phosphorylation of arabinosylcytosine. , 1968, Molecular pharmacology.

[89]  I. Kline,et al.  Sparing action of uridine on the activity of arabinosylcytosine with normal and leukemic mice. , 1968, Cancer research.

[90]  J. Bertino,et al.  Increase of dihydrofolate reductase activity in cultured mammalian cells after exposure to methotrexate. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[91]  D. Schachtschabel,et al.  The effect of 4-aminopyrazolo(3,4-d)pyrimidine and guanine on Ehrlich ascites cells in culture. , 1967, Experimental cell research.

[92]  Paterson Ar,et al.  Combinations of 6-mercaptopurine (NSC-755) and 6-(methylmercapto)purine ribonucleoside (NSC-40774) in therapy of Ehrlich ascites carcinoma. , 1967 .

[93]  M. Hakala,et al.  Comparison of folate reductases of sarcoma 180 cells, sensitive and resistant to amethopterin. , 1967, Molecular pharmacology.

[94]  N. Mantel,et al.  Eradication Of Leukaemic Cells (L1210) by Methotrexate and Methotrexate Plus Citrovorum Factor , 1966, Nature.

[95]  Moore Ec,et al.  Regulation of Mammalian Deoxyribonucleotide Biosynthesis by Nucleotides as Activators and Inhibitors , 1966 .

[96]  R. Parks,et al.  Erythrocytic nucleoside diphosphokinase. II. Isolation and kinetics. , 1966, The Journal of biological chemistry.

[97]  D. R. Dubbs,et al.  HeLa cells resistant to bromodeoxyuridine and deficient in thymidine kinase activity , 1966, International journal of cancer.

[98]  R. Handschumacher.  Conference on obstacles to the control of acute leukemia. Formal discussion: some enzymatic considerations in combination chemotherapy. , 1965, Cancer research.

[99]  C. Heidelberger,et al.  Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: its mechanism of action and inhibition by fluorinated nucleotides. , 1965, Molecular pharmacology.

[100]  A. Sartorelli.  Approaches to the combination chemotherapy of transplantable neoplasms. , 1965, Progress in experimental tumor research.

[101]  B. Magasanik,et al.  REGULATION OF PURINE RIBONUCLEOTIDE SYNTHESIS BY END PRODUCT INHIBITION. THE EFFECT OF ADENINE AND GUANINE RIBONUCLEOTIDES ON THE 5'-PHOSPHORIBOSYL-PYROPHOSPHATE AMIDOTRANSFERASE OF AEROBACTER AEROGENES. , 1965, The Journal of biological chemistry.

[102]  J. Wyngaarden,et al.  THE ENZYMOLOGY OF FEEDBACK INHIBITION OF GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE BY PURINE RIBONUCLEOTIDES. , 1964, The Journal of biological chemistry.

[103]  R. Rubin,et al.  AN ANALYSIS OF THE LACK OF DRUG SYNERGISM DURING SEQUENTIAL BLOCKADE OF DE NOVO PYRIMIDINE BIOSYNTHESIS. , 1964, Cancer research.

[104]  E. F. Zimmerman,et al.  STUDIES ON THE ACTIONS OF PYRAZOLOPYRIMIDINES IN MICROORGANISMS. II. 4-AMINOPYRAZOLOPYRIMIDINE. , 1964, Experimental cell research.

[105]  T. Baba,et al.  THE TRANSPORT OF14 C-LABELED NITROGEN MUSTARD N-OXIDE THROUGH CELLULAR MEMBRANE TREATED WITH TWEEN 80 IN VITRO. , 1963, Gan.

[106]  J. F. Henderson.  Feedback inhibition of purine biosynthesis in ascites tumor cells by purine analogues. , 1963, Biochemical pharmacology.

[107]  M. L. Black.  SEQUENTIAL BLOCKAGE AS A THEORETICAL BASIS FOR DRUG SYNERGISM. , 1963, Journal of medicinal chemistry.

[108]  John Leyden. Webb,et al.  Enzyme and metabolic inhibitors , 1963 .

[109]  S. Bond,et al.  The distribution and fate of iododeoxycytidine in the mouse and rat. , 1962, Cancer research.

[110]  R. Schimke.  Adaptive characteristics of urea cycle enzymes in the rat. , 1962, The Journal of biological chemistry.

[111]  W. Ross.  Increased sensitivity of the Walker tumour towards aromatic nitrogen mustrads carrying basic side chains following glucose pretreatment. , 1961, Biochemical pharmacology.

[112]  M. L. Eidinoff,et al.  Administration of 5-iododeoxyuridine-I-131 in the mouse and rat. , 1961, Cancer research.

[113]  M. Hakala,et al.  Relation of folic acid reductase to amethopterin resistance in cultured mammalian cells. , 1961, The Journal of biological chemistry.

[114]  W. C. Werkheiser.  Specific Binding of 4-Amino Folic Acid Analogues by Folic Acid Reductase , 1961 .

[115]  M. Hakala,et al.  The ability of purine and thymine derivatives and of glycine to support the growth of mammalian cells in culture. , 1959, The Journal of biological chemistry.

[116]  A. Sartorelli,et al.  Metabolic effects of 6-thioguanine. I. Studies on thioguanine-resistant and-sensitive Ehrlich ascites cells. , 1958, Cancer research.

[117]  C. Stock,et al.  Effects of combinations of azaserine and of 6-diazo-5-oxo-L-norleucine with purine analogs and other antimetabolites on the growth of two mouse mammary carcinomas. , 1957, Cancer research.

[118]  M. Hakala.  Prevention of toxicity of amethopterin for sarcoma-180 cells in tissue culture. , 1957, Science.

[119]  N. Mantel,et al.  The employment of combinations of drugs in the chemotherapy of neoplasia: a review. , 1957, Cancer research.

[120]  H. Skipper,et al.  Attempts at dual blocking of biochemical events in cancer chemotherapy. , 1954, Cancer research.

[121]  G. Hitchings,et al.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. , 1954, The Journal of biological chemistry.

[122]  A. Goldin.  Demonstration of protection against the lethal toxicity of 6-mercaptopurine in mice. , 1954, Journal of the National Cancer Institute.

[123]  W. Szybalski,et al.  GENETIC STUDIES ON MICROBIAL CROSS RESISTANCE TO TOXIC AGENTS I. , , 1952, American review of tuberculosis.

[124]  L. Law.  Resistance in Leukemic Cells to an Adenine Antagonist, 6-Mercaptopurine , 1953, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[125]  V. Potter.  Sequential Blocking of Metabolic Pathways in vivo ∗ , 1951, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.